Eledon Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Eledon Pharmaceuticals, Inc.

Sep-03	Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 ELDN GlobeNewswire
Aug-13	Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights ELDN GlobeNewswire
Jun-22	Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus ELDN GlobeNewswire
Jun-08	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine ELDN GlobeNewswire
Jun-04	Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions ELDN ELDN -5.28% GlobeNewswire
May-20	Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress ELDN +7.26% GlobeNewswire
May-13	Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights ELDN GlobeNewswire
Mar-19	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results ELDN -5.00% GlobeNewswire
Mar-16	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine ELDN GlobeNewswire
Mar-10	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation ELDN GlobeNewswire
Mar-04	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference ELDN GlobeNewswire
Feb-05	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 ELDN -8.37% ELDN +11.17% GlobeNewswire
Jan-23	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium ELDN GlobeNewswire
Jan-08	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook ELDN GlobeNewswire
Dec-01	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference ELDN -6.13% GlobeNewswire
Nov-18	Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine ELDN GlobeNewswire
Nov-14	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results ELDN ELDN -7.95% GlobeNewswire
Nov-12	Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants ELDN -11.27% GlobeNewswire
Nov-11	Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants ELDN -5.33% GlobeNewswire
Nov-06	Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting ELDN ELDN -49.76% GlobeNewswire
Nov-05	Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference ELDN GlobeNewswire
Oct-17	Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting ELDN +20.70% GlobeNewswire
Sep-24	Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association ELDN -5.10% GlobeNewswire
Aug-29	Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 ELDN GlobeNewswire
Aug-14	Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results ELDN GlobeNewswire
Aug-06	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation ELDN +9.90% ELDN -20.20% GlobeNewswire
Jul-30	Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 ELDN GlobeNewswire
Jul-17	Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 ELDN GlobeNewswire
Jun-25	Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City ELDN GlobeNewswire
May-14	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results ELDN GlobeNewswire

Eledon Pharmaceuticals, Inc.

Recent Articles by Eledon Pharmaceuticals, Inc.

Upgrade your Finviz experience